TORONTO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX; OTCQB:BSXGF) announces that the Federal Court of Altamira, Pará, Brazil, denied the Company’s request for recognition of provisional compliance with a prior judgment of the Federal Court of Appeals. That appellate judgment conditioned the effectiveness of the Construction License (Licença de Instalação – LI) for the Volta Grande Gold Project on (i) completion of the Indigenous Component Study based on p ...

With the proceeds from the offering, Innventure expects to fully repay all outstanding convertible debenturesORLANDO, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Innventure, Inc. (NASDAQ: INV) (“Innventure” or the “Company”), an industrial growth conglomerate, today announced that it has closed its previously announced registered direct offering of common stock to four institutional investors via a securities purchase agreement. The offering resulted in gross proceeds of approximately $40 million, before deduct ...

Core Insights - Biomerica, Inc. reported financial results for the second quarter of fiscal 2026, highlighting a strategic shift towards higher-margin diagnostic-guided therapy products and the commercialization of its inFoods IBS test [1][6]. Financial Performance - Net sales for the second quarter of fiscal 2026 were $1.21 million, down from $1.64 million in the prior year, primarily due to the absence of large initial distributor orders in the MENA region [9]. - For the six months ended November 30, 2025, net sales were $2.59 million, compared to $3.44 million in the prior year period [10]. - Gross margin for the six-month period was 18%, down from 21% in the prior year, reflecting the transition to higher-margin products [10]. - Operating expenses for the second quarter were $1.42 million, slightly down from $1.43 million in the same period last year [11]. - The net loss for the second quarter was $1.32 million, compared to $0.95 million in the prior year quarter, while the net loss for the six months improved to $1.31 million from $2.27 million in the prior year [12]. Strategic Developments - Biomerica entered a marketing services agreement with Henry Schein to support the commercialization of the inFoods IBS test in the U.S., enhancing awareness among healthcare providers [2]. - The company launched the AI-backed inFoods IBS Trigger Food Navigator, designed to improve dietary compliance for IBS patients by providing personalized meal suggestions [3]. - The Centers for Medicare & Medicaid Services established a national Medicare payment rate of $300 for the inFoods IBS test, effective January 1, 2026, which is expected to enhance patient access [4]. - The Egyptian Drug Authority authorized Biomerica's complete screening test portfolio, facilitating international expansion of its diagnostic products [5]. Management Commentary - The CEO emphasized a strategic pivot from lower-margin products to higher-value diagnostic-guided therapy products, indicating that current revenue softness is a result of this transition rather than a decline in business fundamentals [6]. - The CFO noted a 27% reduction in research and development expenses while continuing to invest in high-value diagnostic programs, indicating a focus on operational efficiency [8].

CONWAY, Ark., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Home BancShares, Inc. (NYSE: HOMB) (“Home” or the “Company”), parent company of Centennial Bank, released quarterly earnings today. Quarterly Highlights MetricQ4 2025Q3 2025Q2 2025Q1 2025Q4 2024Net income$118.2 million$123.6 million$118.4 million$115.2 million$100.6 millionNet income, as adjusted (non-GAAP)(1)$117.9 million ...

AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide (CGRP) antagonist treatment option for both pediatric and adult patients.1,2Results from the SPACE trial found AJOVY significantly reduced monthly migraine days and monthly headache days versus placebo over a 12-week period in pediatric patients with episodic migraine.1The U.S. Food and Drug Administration (FDA) approved AJOVY in August 2025 for the preventive treatmen ...

CALGARY, Alberta, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) plans to release its financial results and operating highlights for the year ended December 31, 2025, on Thursday, February 26, 2026 prior to market open. Results will be communicated by news release and will be available on the Company's website at www.enerflex.com and under the electronic profile of the Company on SEDAR+ and EDGAR at www.sedarplus.ca and www.sec.gov/edgar, respectively. ...

Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorderBOSTON and LONDON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on developing transformational medicines, today announced the presentation of new preclinical data showing that OX2R activation with a highly potent and selective OX2R agonist reduced behavioral despair and enhanced wakefulness ...

All amounts are in United States dollars, unless otherwise stated. TORONTO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today reported fourth quarter and annual 2025 production. The Company expects to provide updated three-year production and operating guidance in February 2026, coinciding with the completion of the Expansion Study for the Island Gold District. “Our fourth quarter production totaled 141,500 ounces, consistent with the third quarter but ...

TORONTO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Golconda Gold Ltd. (“Golconda Gold” or the “Company”) (TSX-V: GG; OTCQB: GGGOF) is pleased to announce that Alan Linden has been appointed as the General Manager of the Corporation’s Summit mine, located in New Mexico, United States. Alan Linden has over 35 years’ experience as a Mining Engineer and Project Manager with a focus on underground mining and mine restart and expansion projects. Most recently working for a large multi-national mining contractor, Alan has ...

MIAMI BEACH, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Herzfeld Credit Income Fund, Inc. (NASDAQ: HERZ) (the “Fund”) today announced the estimated net asset value (“NAV”) of the Fund as of December 31, 2025 was $2.14. About Thomas J. Herzfeld Advisors, Inc. Thomas J. Herzfeld Advisors, Inc., founded in 1984, is an SEC registered investment advisor, specializing in investment analysis and account management in closed-end funds. More information about the advisor can be found at www.herzfeld.com. Past performan ...